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INTRODUCTION 
Tuberculosis (TB) is an infectious bacterial disease mainly caused by Mycobacterium tuberculosis 
(M.tb). TB is a respiratory transmitted disease affecting nearly 32% of the world’s population. The 
last data published by WHO established that there were an estimated 9.4 million incident cases 
and 11.1 million prevalent cases of TB in 2008, killing 1.3 million people worldwide [1]. The 
continuing emergence of multidrug-resistant and extremely drug-resistant strains of M.tb and the 
increasing incidences of the disease in immune-compromised patients highlights the urgent need 
for new drugs which could shorten the treatment duration and extend the range of effective TB 
treatment options [2, 3]. 
Quinoxaline derivatives show very interesting biological properties and several studies have been 
published demonstrating their capability to act not only as antibacterial and antimicrobial but also 
as antitumoral agents [4-7] (Fig. 1). 
As a result of the anti-tuberculosis research project, our group has published several papers in 
which the synthesis and biological evaluation of a large number of quinoxaline and quinoxaline 
1,4-di-N-oxide derivatives have been described [8-14]. These studies have facilitated a wide 
structure-activity relationship (SAR) analysis which lead us to design a group of seventy-seven 
3-methylquinoxaline-2-carboxamide 1,4-di-N-oxide derivatives that were prepared and tested 
against M.tb [15,16].  
This project allowed us to observe that the lack of one or both of the N-oxide groups generally 
led to the loss of the antimycobacterial activity [17, 18]. The well-known N-oxide bio-reduction 
process and its biological consequences seem to be essential for the biological activity 
displayed by heterocyclic di-N-oxides although little is known about their mode of action [19, 
20]. 
Several studies have investigated and reported the electrochemical behavior of quinoxaline di-
N-oxides and demonstrated reasonable correlations between electrochemical behavior, 
structure and drug activity [21-23]. Not only heterocyclic di-N-oxides but also antibacterial 
quinones and heterocyclic nitro derivatives have revealed that compounds showing less 
negative reduction potential values exhibited more powerful antibacterial activity [24]. 
These studies were performed under the hypothesis of the iminium theory. It was proposed that 
iminium species, which are believed to be generated metabolically in vivo, could take part in 
charge transfer (CT) processes, resulting in the formation of superoxide and generating toxic 
oxy radicals. At this point we decided to study the electrochemical properties of quinoxaline di-
N-oxide derivatives which possess the suitable structural requirement and should be easily 
reduced due to their electrophilic nature and the stability of the resulting radical which is 
stabilized by resonance [22, 24, 25]. 
The experimental goal of this study was to determine the reduction potentials for several series 
of quinoxaline di-N-oxides in order to obtain evidence of the relationship between the 
electrochemical behaviour and the anti-tuberculosis activity. 
 
EXPERIMENTAL 
Chemical synthesis and anti-tuberculosis activity 
The methods for the synthesis of quinoxaline-2-carboxamide 1,4-di-N-oxide derivatives were 
reported elsewhere [15,16]. 
Pharmacology 
In vitro evaluation of the anti-tuberculosis activity was carried out within the Tuberculosis 
Antimicrobial Acquisition & Coordinating Facility (TAACF) screening program for the discovery 
of novel drugs for the treatment of tuberculosis. The Southern Research Institute coordinates 
the overall program under the direction of the U.S. National Institute of Allergy and Infectious 
Disease (NIAID). [26] 
The purpose of the screening program is to provide a resource whereby new 
experimental compounds can be tested for their ability to inhibit the growth of virulent 
Mycobacterium tuberculosis (M.Tbc.). Biological tests have been performed according to 
previously described methods. 
The initial screening is conducted against M.Tbc. H37Rv (ATCC 27294) in BACTEC 12B 
medium using the Microplate Alamar Blue Assay (MABA).[32] Compounds are tested in ten 2-
fold dilutions, typically from 100 µg/mL to 0.19 µg/mL. The IC90 is defined as the concentration 
effecting a reduction in fluorescence of 90% relative to controls. This value is determined from 
the dose-response curve using a curve-fitting program. Any IC90 value of 10µg/mL is 
considered "Active" for antitubercular activity. 
The VERO cell cytotoxicity assay is carried out in parallel with the TB Dose Response 
assay. After 72 hours exposure, viability is assessed using Promega’s Cell Titer Glo 
Luminescent Cell Viability Assay, a homogeneous method for determining the number of viable 
cells in culture based on quantitation of the ATP present. Cytotoxicity is determined from the 
dose-response curve as the CC50 using a curve fitting program. Then the CC50 is divided by the 
IC90 for calculating a Selectivity Index (SI) value. SI values of  10 are considered for further 
testing. 
Electrochemistry 
Dimethylformamide (DMF) and tetrabutylammonium perchlorate (TBAP) were obtained 
commercially in the highest purity available and used without further purification. Ferrocene was 
obtained from the Aldrich Chemical Company. Cyclic voltammetric experiments were carried 
out on a CHI Instruments 630 voltammetric analyzer. Test solutions contained 0.5 mM of the 
desired compound and 0.1 M TBAP. Scan rates ranged from 50 mV/s to 500 mV/s. Half-wave 
potentials (E1/2) were measured as the average of the cathodic and anodic peak potentials [27]. 
For first derivative cyclic voltammograms, Epc was determined at the point where the derivative 
curve crosses the baseline [27]. 
A three electrode cell was used for all electrochemical experiments, consisting of a Pt-disk (1.6 
mm) electrode, a Pt-wire auxilliary electrode, and a Ag/AgNO3 (0.1 M in acetonitrile) reference 
electrode (SRE). Deoxygenation of all solutions was accomplished by passing a gentle, 
constant stream of prepurified dinitrogen through the solution for 15 minutes and maintaining a 
blanket of the inert gas over the solution during the experiment. To account for daily variations 
in the reference electrode and liquid junction potentials, ferrocene (Fc) was added to each 
solution following measurements of the test compound, and used as an internal reference 
redox system [28]. All potentials are reported versus the ferrocene/ferrocinium (Fc/Fc+) redox 
couple, i.e. Epc, SRE – E1/2, Fc/Fc+ or E1/2, SRE – E1/2, Fc/Fc+. 
 
RESULTS AND DISCUSSION 
Electrochemical behavior 
 The present study included several series of 37 quinoxaline-di-N-oxides. The redox 
properties of these substances were studied using cyclic voltammetry and first derivative cyclic 
voltammetry in DMF with TBAP as supporting electrolyte. Results are included as supplementary 
information and representative voltammograms are provided in Figure 1. All reductions were 
found to be diffusion controlled, as indicated by constant current functions at varying scan rates. 
[27, 29]  
 For all compounds studied, two cyclic voltammetric waves were observed between -0.4 
and -1.9 V during reduction. The first voltammetric wave was irreversible under these conditions, 
with peak potentials, Epc,1, ranging from -1.21 to -1.65 V (vs. Fc/Fc+). For compounds 18-21, 23, 
24, 27, 28, 31, and 33, this wave appeared as a shoulder to the second wave in the 
voltammogram. With a few exceptions (see following), the second voltammetric wave was 
quasireversible under the conditions used in the study, with peak potentials, Epc,2, ranging 
between -1.39 and -1.92 V, and half-wave potentials ranging between -1.42 and -1.80 V. For 
compounds 1, 8, 16, 17, and 31 this voltammetric wave was not very well defined, appearing as a 
shoulder in the cyclic voltammogram. Values of ∆Ep for this wave (100 mV/s) were generally 
greater than theoretical for a reversible, one-electron reduction, and increased with increasing 
scan rate. For compounds 3, 9, 12, 22, and 26, the second voltammetric wave was irreversible 
under the conditions utilized in this study. Calculated ipa/ipc ratios for compounds 2, 5-8, 11, 13, 15, 
21, 23, 24, 27, 29-35, and 37 were close to unity (0.61 to 1.24) at all scan rates, indicating the 
formation of relatively stable reduction products for this process on the time scale of the 
voltammetric scans. Current ratios that deviated significantly from unity (0.24 to 0.55) were 
observed for all other derivatives, indicative of greater kinetic or other complications following the 
reduction [29]. No reduction waves were observed at potentials negative of the second 
voltammetric wave for these quinoxaline-1,4-dioxide derivatives under the conditions used in this 
study, with the exception of compounds 3-5, 9-12, 22, 26, 33 and 37. For the latter compounds, a 
third irreversible reduction wave was observed at potentials ranging from -1.885 to -2.414 V. 
 Examination of the data indicates the influence of quinoxaline structure on potential.  The 
37 compounds can be broken down into 9 different analogues based on structure, with the mono 
chloro and methyl substituted quinoxalines existing as mixtures of 6- and 7-substituted positional 
isomers. Within each analogous series, replacement of the 6-/7-hydrogen atom with a single 
electron-withdrawing substituent group, i.e. chloro, fluoro, and trifluoromethyl, resulted in a 
positive shift in the peak potentials for both voltammetric waves, whereas replacement of the 6-/7-
hydrogen atom with a single electron-releasing methyl group resulted in a negative shift. As an 
example, comparison of the potentials for compounds 13 and 15 shows that replacement of the 
hydrogen atom with the chloro group resulted in a +109 mV potential shift for the first voltammetric 
wave, and a +76 mV shift in the second voltammetirc wave (+105 mV shift in E1/2). Replacing the 
hydrogen atom in compound 13 with the methyl group in compound 14 resulted in a -20 mV 
potential shift for the first voltammetric wave, and a -10 mV shift in the second voltammetric wave 
(-8 mV shift in E1/2). Similarly, comparison of compound 6 with compounds 10 and 11 shows that 
substituting the 7-hydrogen with trifluoromethyl or fluoro groups results in a +186 mV and +74 mV 
shift in the first voltammetric wave, respectively. The reduction potentials for the quinoxaline 
derivatives within each analogue generally fit the modified Hammett equation, ∆E1/2 = ρpiRσx 
(correlation coefficients ranged from 0.89 to 1), where σx is the polar inductive electronic 
substituent constant taken as the average of the sum of σm-x  and σp-x, and ρ is the reaction 
constant [30]. (Figure 2) (For quinoxaline derivatives substituted in the benzene ring, the use of 
(σm-x  + σp-x)/2 has been recommended[31].) These effects are consistent with facilitation of 
reduction by a positive charge at the site of reduction [30], in keeping with previous reports [22, 
25, 30, 32, 34]. Addition of a second electron-withdrawing group, i.e. chloro or fluoro, enhances 
this effect. For example. comparison of the 6-,7-dichloro derivatives (3, 9, 22, 26, 33 and 37) with 
the corresponding 6-/7-chloro derivatives (2, 8, 21, 25, 32 and 36) shows that addition of the 
second chloro group shifts the potential of the first voltammetric wave positively by +81 to +271 
mV, and that of the second voltammetric wave by +121 to +395 mV. No apparent correlation was 
observed between substitution in the amide side chain and potential (cf. 1, 14, 17, 20, 24, 28, 31 
and 35). In the latter case, the substituents are presumably too far removed from the site of 
reduction. 
Relationship between electrochemical behavior and anti-tuberculosis activity 
With regards to the mechanism, heterocyclic di-N-oxides possessing the diiminium 
structure are expected to undergo one electron reduction to form a radical anion [32, 35-38] 
(Figure 3), and in fact reduction of quinoxaline 1,4-di-N-oxide in DMF has been shown via ESR 
and cyclic voltammetry to involve the nitrone function to form the radical anion [33]. The 
electrochemical reductions of quinoxaline 1, 4-di-N-oxides in aprotic solvent systems have been 
reported previously [22, 25, 32-34]. In most cases, a reversible reduction wave attributed to 
reduction of the N-oxide functionality has been reported in DMF in the vicinity of those observed 
in the present study [22, 25, 32, 33]. For the compounds in the present study, electrochemical 
reduction in DMF is consistent with reduction of the N-oxide functionality to form a radical anion 
as well. The second reduction wave observed could be due to the formation of the dianion, or to 
reduction of the product formed from a chemical step involving the radical anion [34]. The latter 
is supported by the irreversibility of the first reduction wave. Kaye and Stonehill pointed out that 
an objection to the iminium theory is that some potentials observed are too negative although 
several reports indicate that reduction potential in vivo may be better than in vitro [24], and N-
oxides are known to undergo bioreduction [19, 20].  
No absolute correlation can be established between the reduction potential and the 
biological activity. Nevertheless, within the compounds which have shown biological activity (1-
12) (Table 1) it can be said that the less negative the reduction potential is, the more active the 
compounds are. In fact, for compounds showing a Epc,1<-1.6V the IC90 increases almost 
exponentially (Figure 4). Not only that, but compounds showing a Epc,1<-1.6V also present a 
selectivity index (SI) much lower than compounds with a reduction potential that is less negative 
(Figure 5). Of course, absolute correlation between electrochemical behavior and anti-
tuberculosis activity is not reasonable as many other factors should be considered: solubility, 
metabolism, absorption or site binding among others. The results support the participation of 
charge transfer processes in the mechanism of action of quinoxaline di-N-oxides; however, the 
exact mechanism was not investigated further. 
 
CONCLUSIONS 
Thirty-seven quinoxaline di-N-oxides have been studied and all of them showed two cyclic 
voltammetric waves between -0.4 and -1.9 V during reduction. The first voltammetric wave was 
irreversible for all the studied compounds under the conditions of the study. A relationship 
between electrochemical behavior and quinoxaline structure can be established and it can be 
said that the insertion of an electron-withdrawing group on the quinoxaline ring results in a less 
negative reduction potential and makes the bio-reduction more facile. Nevertheless, no 
relationship could be found between substitution on the amide chain and the reduction 
potential. These results are expected to offer new insights into the study of the mechanism of 
action for future antitubercular drugs. 
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